Cargando…
The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
Background: Studies evaluating the prognostic significance of programmed death-ligand 1 (PD-L1) expression in colorectal cancer (CRC) are limited and remain controversial. This meta-analysis was conducted in order to evaluate the clinicopathological and prognostic significance of PD-L1 expression in...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403169/ https://www.ncbi.nlm.nih.gov/pubmed/30873025 http://dx.doi.org/10.3389/fphar.2019.00139 |
_version_ | 1783400529187045376 |
---|---|
author | Li, Yan He, Meizhi Zhou, Yaoyao Yang, Chen Wei, Shuyi Bian, Xiaohui Christopher, Odong Xie, Lang |
author_facet | Li, Yan He, Meizhi Zhou, Yaoyao Yang, Chen Wei, Shuyi Bian, Xiaohui Christopher, Odong Xie, Lang |
author_sort | Li, Yan |
collection | PubMed |
description | Background: Studies evaluating the prognostic significance of programmed death-ligand 1 (PD-L1) expression in colorectal cancer (CRC) are limited and remain controversial. This meta-analysis was conducted in order to evaluate the clinicopathological and prognostic significance of PD-L1 expression in CRC patients. Methods: A comprehensive search was performed against the Medline/PubMed, Embase, Cochrane Library, Web of Science (WoS) and Scopus databases. Data were extracted with name of the first author, year of publication, country of origin, tumor type, number of cases, staining method, cut-off values, PD-L1 positive expression, clinicopathological parameters, outcome, and quality assessment score, and statistical analysis was conducted using Review Manager Version 5.3 (Revman the Cochrane Collaboration; Oxford, England) and STATA version 14 (Stata Corporation; College Station, TX, USA). Results: Ten studies were included in this meta-analysis, in which the pooled hazard ratio (HR) showed that PD-L1 expression in tumor cells was significantly associated with a poor overall survival (HR = 1.50, 95% CI 1.05–2.13, P = 0.03). The pooled HR for disease-free survival (DFS) indicated that PD-L1 expression was significantly associated with shorter DFS (HR = 2.57, 95% CI 1.40–4.75, P = 0.002). The pooled odds ratios (ORs) showed that PD-L1 expression was associated with poor differentiation (OR = 3.47, 95% CI 1.37–8.77, P = 0.008) and right colon cancer (OR = 2.38, 95% CI 1.57–3.60, P < 0.0001). However, the expression of PD-L1 was independent of gender, age, tumor size, tumor stage, lymph node metastasis, and tumor-node metastasis stage. Conclusion: This meta-analysis indicated that a high level of PD-L1 expression might be a biomarker for a poor prognosis in CRC patients. This information may be helpful for clinicians to stratify CRC patients for anti-PD-1/PD-L1 therapy, particularly patients with microsatellite instability high (MSI-H). |
format | Online Article Text |
id | pubmed-6403169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64031692019-03-14 The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis Li, Yan He, Meizhi Zhou, Yaoyao Yang, Chen Wei, Shuyi Bian, Xiaohui Christopher, Odong Xie, Lang Front Pharmacol Pharmacology Background: Studies evaluating the prognostic significance of programmed death-ligand 1 (PD-L1) expression in colorectal cancer (CRC) are limited and remain controversial. This meta-analysis was conducted in order to evaluate the clinicopathological and prognostic significance of PD-L1 expression in CRC patients. Methods: A comprehensive search was performed against the Medline/PubMed, Embase, Cochrane Library, Web of Science (WoS) and Scopus databases. Data were extracted with name of the first author, year of publication, country of origin, tumor type, number of cases, staining method, cut-off values, PD-L1 positive expression, clinicopathological parameters, outcome, and quality assessment score, and statistical analysis was conducted using Review Manager Version 5.3 (Revman the Cochrane Collaboration; Oxford, England) and STATA version 14 (Stata Corporation; College Station, TX, USA). Results: Ten studies were included in this meta-analysis, in which the pooled hazard ratio (HR) showed that PD-L1 expression in tumor cells was significantly associated with a poor overall survival (HR = 1.50, 95% CI 1.05–2.13, P = 0.03). The pooled HR for disease-free survival (DFS) indicated that PD-L1 expression was significantly associated with shorter DFS (HR = 2.57, 95% CI 1.40–4.75, P = 0.002). The pooled odds ratios (ORs) showed that PD-L1 expression was associated with poor differentiation (OR = 3.47, 95% CI 1.37–8.77, P = 0.008) and right colon cancer (OR = 2.38, 95% CI 1.57–3.60, P < 0.0001). However, the expression of PD-L1 was independent of gender, age, tumor size, tumor stage, lymph node metastasis, and tumor-node metastasis stage. Conclusion: This meta-analysis indicated that a high level of PD-L1 expression might be a biomarker for a poor prognosis in CRC patients. This information may be helpful for clinicians to stratify CRC patients for anti-PD-1/PD-L1 therapy, particularly patients with microsatellite instability high (MSI-H). Frontiers Media S.A. 2019-02-28 /pmc/articles/PMC6403169/ /pubmed/30873025 http://dx.doi.org/10.3389/fphar.2019.00139 Text en Copyright © 2019 Li, He, Zhou, Yang, Wei, Bian, Christopher and Xie. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Li, Yan He, Meizhi Zhou, Yaoyao Yang, Chen Wei, Shuyi Bian, Xiaohui Christopher, Odong Xie, Lang The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis |
title | The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis |
title_full | The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis |
title_fullStr | The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis |
title_full_unstemmed | The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis |
title_short | The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis |
title_sort | prognostic and clinicopathological roles of pd-l1 expression in colorectal cancer: a systematic review and meta-analysis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403169/ https://www.ncbi.nlm.nih.gov/pubmed/30873025 http://dx.doi.org/10.3389/fphar.2019.00139 |
work_keys_str_mv | AT liyan theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis AT hemeizhi theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis AT zhouyaoyao theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis AT yangchen theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis AT weishuyi theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis AT bianxiaohui theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis AT christopherodong theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis AT xielang theprognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis AT liyan prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis AT hemeizhi prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis AT zhouyaoyao prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis AT yangchen prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis AT weishuyi prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis AT bianxiaohui prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis AT christopherodong prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis AT xielang prognosticandclinicopathologicalrolesofpdl1expressionincolorectalcancerasystematicreviewandmetaanalysis |